	US 12,337,015 B2
	Myoblast chimeric cells (MCCs)
Maria Siemionow, Chicago, IL (US)
Assigned to DYSTROGEN THERAPEUTICS CORPORATION, Chicago, IL (US)
Appl. No. 17/439,210
Filed by Dystrogen Therapeutics Corporation, Chicago, IL (US)
PCT Filed Mar. 13, 2020, PCT No. PCT/US2020/022712 § 371(c)(1), (2) Date Sep. 14, 2021, PCT Pub. No. WO2020/186197, PCT Pub. Date Sep. 17, 2020.
Claims priority of provisional application 62/818,435, filed on Mar. 14, 2019.
Prior Publication US 2022/0160783 A1, May 26, 2022
Int. Cl. A61K 35/34 (2015.01); C12N 5/077 (2010.01); C12N 5/12 (2006.01)

CPC A61K 35/34 (2013.01) [C12N 5/0658 (2013.01); C12N 5/12 (2013.01)]

11 Claims

1. A method of generating myoblast chimeric cells comprising:

a) establishing:

i) a MD (muscle disease) cell culture comprising MD non-passaged myoblast cells derived from a first human subject with a muscle disease (MD), and

ii) a Donor cell culture comprising non-passaged Donor myoblast cells derived from a second human subject without said MD;

b) culturing and passaging said MD cell culture, and said Donor cell culture, at least twice and not more than four times, to generate:

i) a population of 2-4 times passaged MD myoblasts, and

ii) a population of 2-4 times passaged Donor myoblasts;

c) combining at least a portion of said population of 2-4 times passaged MD myoblasts, with at least a portion of said population of 2-4 times passaged Donor myoblasts, to generate a cell mixture, and

d) adding a cell-fusion solution to said cell mixture to generate a cell fusion reaction such that a population of myoblast chimeric cells (MCCs) is generated, wherein each of said MCCs comprises: i) one of said 2-4 times passaged MD myoblasts, and ii) one of said 2-4 times passaged Donor myoblasts.